Intestinal metaplasia, dysplasia, gastric cancer and Helicobacter pylori: Epidemiological observations;Metaplasia intestinale, displasia, cancro gastrico e Helicobacter pylori: Considerazioni epidemiologiche

Minerva Medica

Volumn 96, Issue 1, 2005, Pages 1-10

  Pellicano, R ^a   Fagoonee, S ^b   Palestro, G ^b   Rizzetto, M ^a   Ponzetto, A ^a,c  

^a Bone Marrow Transplant Unit   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Dysplasia; Helicobacter pylori; Intestine; Metaplasia; Stomach neoplasms

Indexed keywords

CARCINOGEN;

CANCER DIAGNOSIS; CANCER GROWTH; CELL HETEROGENEITY; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSPLASIA; GEOGRAPHIC DISTRIBUTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; LYMPHOMA; MORBIDITY; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; STOMACH CANCER;

ADENOCARCINOMA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METAPLASIA; STOMACH NEOPLASMS;

EID: 28644448805     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. Ca Cancer J Clin 2000;50:7-33.
3. Kocher HM, Linklater K, Patel S, Ellul JP. Epidemiological study of oesophageal and gastric cancer in south-east England. Br J Surg 2001;88:1249-57.
4. Medrado-Faria MA, Rodrigues de Almeida JW, Zanetta DM. Gastric and colorectal cancer mortality in an urban and industrialized area of Brazil. Rev Hosp Clin Fac Med Sao Paulo 2001;56:47-52.
5. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990;65:1255-60.
6. Oshima A, Hirata N, Ubukata T, Umeda K, Fujimoto I. Evaluation of a mass screening program for stomach cancer with a case-control study design. Int J Cancer 1986;38:829-33.
7. Kampschoer GH, Fujii A, Masuda Y. Gastric cancer detected by mass survey: comparison between mass survey and outpatient detection. Scand J Gastroenterol 1989;24:813-7.
8. Kubota H, Kotoh T, Masunaga R, Dhar DK, Shibakita M, Tachibana M et al. Impact of screening survey of gastric cancer on clinicopathological features and survival: retrospective study at a single institution. Surgery 2000;128:41-7.
9. Locke III GR, Talley NJ, Carpenter HA, Harmsen WS, Zinsmeister AR, Melton LJ III. Changes in the site- and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology 1995;109:1750-6.
10. Muñoz N, Franceschi S. Epidémiologie du cancer gastrique. In: Mégraud F, Lamouliatte H, editors. Helicobacterpylori. Paris: Elsevier: 1997. vol.2, p. 177-203.
11. De Angelis R, Valente F, Frova L, Capocaccia R, Micheli A, Chessa E et al. Incidence, mortality and prevalence of stomach cancer in Italian regions. Tumori 1996;82:314-20.
12. Zanetti R, Crosignani P, Rosso S. Il cancro in Italia. I dati di incidenza dei registri tumori. Roma: Il Pensiero Scientifico Editore; 1997.
13. Gatta G, Buiatti E, Conti E, De Lisi V, Falcini F, Federico M et al. Variations in the survival of adult cancer patients in Italy. Tumori 1997;83:497-504.
14. Barchielli A, Amorosi A, Balzi D, Crocetti E, Nesi G. Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985-1987. Eur J Cancer 2001;37:1674-80.
15. Nishimura Y, Mitsutake N, Nakanishi S, Konishi T. Cost analysis on stomach cancer treatment in Japanese hospitals. Gan To Kagaku Ryoho 2000;27:1360-8.
16. Koyama K, Ito M, Kotanagi H. Improvement of the efficiency of the treatment of gastric cancer by the standardization of the treatment plan. Gan To Kagaku Ryoho 2000;27:1375-9.
17. Elixhauser A, Halpern MT. Economic evaluation of gastric and pancreatic cancer. Hepatogastroenterology 1999;46:1206-13.
18. Bollschweiler E, Boettcher K, Hoelscher AH, Sasako M, Kinoshita T, Maruyama K et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 1993;71:2918-25.
19. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? "What are the suggestions? Crit Rev Oncol Hematol 2001;40:77-94.
20. Green PH, O'Toole KM, Slonim D, Wang T, Weg A. Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. Am J Med 1988;85:658-61.
21. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. Helicobacterpylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
22. Stael von Holstein C, Eriksson S, Huldt B, Hammar E. Endoscopie screening during 17 years for gastric stump carcinoma: a prospective clinical trial. Scand J Gastroenterol 1991;26:1020-6.
23. Park DI, Rhee PL, Kim JE, Hyun JG, Kim YH, Son HJ et al. Risk factors suggesting malignant transformation of gastric adenoma: univariate and multivariate analysis. Endoscopy 2001;33:501-6.
24. Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001;10:793-8.
25. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol 1985;12:11-8.
26. Tytgat GN. Review article: practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer. Aliment Pharmacol Ther 1998;12:123-8.
27. Hosokova O, Tsuda S, Kidani E. Diagnosis of gastric cancer up to three years after negative upper GI endoscopy. Endoscopy 1998;30:669-674.
28. Stanghellini V, Anti M, Bianchi Porro G, Corinaldesi R, Gasbarrini G, Giacosa A et al. Risk indicators of organic diseases in uninvestigated dyspepsia: a one-week survey in 246 Italian endoscopy units. Eur J Gastroenterol Hepatol 1999;11:1129-34.
29. Breslin NP, Thomson ABR, Bailey RJ, Blustein PK, Meddings J, Lalor E et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000;46:93-7.
30. Maconi G, Kurihara H, Panizzo V, Russo A, Cristaldi M, Marrelli D et al. Gastric cancer in young patients with no alarm symptoms: focus on delay in diagnosis, stage of neoplasm and survival. Scand J Gastroenterol 2003;38:1249-55.
31. Luk GD. Tumors of the stomach. In: Feldman M, editor. Sleisenger & Fordtran's gastrointestinal and liver disease. Philadelphia: WB Saunders Company; 1998.p. 733-57.
32. Ectors N. Anatomopathologie du cancer gastrique. In: Mégraud F, Lamouliatte H, editors. Helicobacterpylori. Paris: Elsevier; 1997;2:221-41.
33. Axon A. Early gastric cancer revisited. Ital J Gastro-enterol Hepatol 1999;31:357-8.
34. Keighley MRB. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003;18 Suppl 3:7-30.
35. Kyriazanos ID, Ilias I, Gizaris V, Hountis P, Georgaklis V, Dafnopoulou A et al. Seroepidemiology of Helicobacter pylori infection in hellenic navy recruits. Eur J Epidemiol 2001;17:501-4.
36. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000;181:1359-63.
37. International Agency for Research on Cancer. World Health Organization. Infection with Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC; 1994.p.177-202.
38. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-60.
39. Filipe MI, Jass JR. Intestinal metaplasia subtypes and cancer risk. In: Filipe MI, Jass JR editors. Gastric carcinoma. Edinburgh: Churchill Livingstone; 1986.p.97.
40. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994;57:324-9.
41. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
42. Palli D. Gastric cancer and Helicobacter pylori: a critical evaluation of the epidemiological evidence. Helicobacter 1997;2:S50-5.
43. Salmi LR, Collet JP. Critical reading of medical articles. IV. To determine the causes. Rev Prat 1992;42:213-8. French.
44. Ernster VL. Nested case-control studies. Prev Med 1994;23:587-90.
45. Greenhalgh T. Evidence-based medicine. Le basi. (Ed. Ital.). Torino: Infomedica; 1998.
46. Egger M, Smith GD. Meta-analysis bias in location and selection of studies. BMJ 1998;316:61-6.
47. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
48. Sepulveda AR, Coelho LGV. Helicobacter pylori and gastric malignancies. Helicobacter 2002; 7 Suppl 1:37-42.
49. Working Party of the European Helicobacter pylori Study Group. Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997;41:S1-23.
50. Parsonnet DM, Friedman GT, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N et al. Helicobacter pylori infection and the risk of gastric cancer. N Engl J Med 1991;325:1127-31.
51. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez G, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991;325:1132-6.
52. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N et al. Association between infection with Helicobacter pylori and risk of gastric cancer; evidence of a prospective investigation. BMJ 1991;302:1302-5.
53. Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K et al. Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population. Arch Intern Med 2000;160:1962-8.
54. Ohata H, Kitauchi S, Yoshimura N, Mugitand K, Iwane M, Nakamura H et al. Progression of chronic atrophie gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
55. Ponzetto A, DeGiuli M, Sanseverino P, Soldati T, Bazzoli F. Helicobacter pylori ana atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1996;88:465.
56. Fiocca R, Luinetti, Villani L, Chiaravalli A, Cornaggia M, Stella G et al. High incidence of Helicobacter pylori colonization in early gastric cancer and the possible relationship to carcinogenesis. Eur J Gastroenterol Hepatol 1993;5:S2-S8.
57. Menegatti M, Vaira D, Miglioli M, Holton J, Vergura MR, Biasco G et al. Helicobacter pylori in patients with gastric and nongastric cancer. Am J Gastroenterol 1995:90:1278-81.
58. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori sero-positivity and gastric cancer. Gastroenterology 1998;114:1169-79.
59. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case-control studies nested within prospective cohorts. Gut 2001;49:347-53.
60. Xue F, Xu Y, Wan Y, Pan B, Ren J, Fan D. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. World J Gastroenterol 2001;5:801-5.
61. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis on the relationship between cagA sero-positivity and gastric cancer. Gastroenterology 2003;125:1636-44.
62. Miehlke S, Kirsch C, Agha-Amiri K, Gunther T, Lehn N, Malfertheiner P et al. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 2000;87:322-7.
63. De Figueiredo Soares T, de Magalhaes Queiroz DM, Mendes EN, Rocha GA, Rocha Oliveira AM, Alvares Cabral MM et al. The interrelationship between Helicobacter pylori vacuolating cytotoxin and gastric carcinoma. Am J Gastroenterol 1998;93:184l-7.
64. Rugge M, Busatto G, Cassaro M, Shiao YH, Russo V, Leandro G et al. Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer 1999;85:2506-11.
65. Wong BC, Lam SK, Ghing CK, Hu WH, Ong LY, Chen BW et al. Seroprevalence of cytotoxin-associated gene A positive Helicobacterpylori strains in Changle, an area with very high prevalence of gastric cancer in South China. Aliment Pharmacol Ther 1999;13:1295-302.
66. Webb PM, Crabtree JE, Forman D. Gastric cancer, cytotoxin-associated gene A-positive Helicobacter pylori, and serum pepsinogens: an international study: The Eurogast Study Group. Gastroenterology 1999;116:269-76.
67. Rudi J, Muller M, Von Herbay A, Zuna I, Raedsch R, Stremmel W, Rath U. Lack of association of Helicobacter pylori seroprevalence and gastric cancer in a population with lowe gastric cancer incidence. Scand J Gastroenterol 1995;30:958-63.
68. Wong BC, Ching CK, Lam SK, Li ZL, Chen BW, Li YN et al. Differential north to south gastric cancer-duodenal ulcer gradient in China. China Ulcer Study Group. J Gastroenterol Hepatol 1998;13:1050-7.
69. Molloy RM, Sonnenberg A. Relation between gastric cancer and previous peptic ulcer disease. Gut 1997; 40:247-52.
70. Wu MS, Hung HW, Wang JT, Tseng CC, Shun CT, Wang HP et al. Helicobacter pylori-seronegative gastric carcinoma: a subset of gastric carcinoma with distinct clinicopathologic features. Hepatogastroenterology 1998; 45:2432-6.
71. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med 1999; 159:142-8.
72. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4.
73. Forbes GM, Threlfall TJ. Treatment of Helicobacter pylori infection to reduce gastric cancer incidence: uncertain benefits of a community based programme in Australia. J Gastroenterol Hepatol 1998;13:1091-5.
74. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999;13:851-6.